Sitbon O, Morrell N: Pathways in pulmonary arterial hypertension: The future is here. Eur Respir Rev 2012;21:321.
Paulis L et al: New developments in the pharmacological treatment of hypertension: Dead-end or a glimmer at the horizon? Curr Hypertens Rep 2015;17:557.
White CM et al: Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders. CNS Neurol Disord Drug Targets 2010;9:661.
Garcia-Recio S, Gascon P: Biological and pharmacological aspects of the NK1receptor. Biomed Res Int 2015;2015:495704.
Mistrova E et al: Role of substance P in the cardiovascular system. Neuropeptides 2016;58:41.
Munoz M, Covenas R: Involvement of substance P and the NK-1 receptor in cancer progression. Peptides 2013;48C:1.
Boules M et al: Diverse roles of neurotensin agonists in the central nervous system. Front Endocrinol 2013;4:36.
Hwang JI et al: Phylogenetic history, pharmacological features, and signal transduction of neurotensin receptors in vertebrates. Ann N Y Acad Sci 2009;1163:169.
Osadchii OE: Emerging role of neurotensin in regulation of the cardiovascular system. Eur J Pharmacol 2015;762:184.
Tajti J et al: Migraine and neuropeptides. Neuropeptides 2015;2:19.
Walker CS et al: Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci 2010;31:476.
Wrobel Goldberg S, Silberstein SD: Targeting CGRP: A new era for migraine treatment. CNS Drugs 2015;29:443.
Kato J, Kitamura K: Bench-to-bedside pharmacology of adrenomedullin. Eur J Pharmacol 2015;764:140.
Koyama T et al: Adrenomedullin-RAMP2 system in vascular endothelial cells. J Atheroscler Thromb 2015;22:647.
Maguire JJ, Davenport AP: Endothelin@25: new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12. Br J Pharmacol 2014;171:5555.
Nishikimi T et al: Adrenomedullin in cardiovascular disease: A useful biomarker, its pathological roles and therapeutic application. Curr Protein Pept Sci 2013;14:256.
Woolley MJ, Conner AC: Comparing the molecular pharmacology of CGRP and adrenomedullin. Curr Protein Pept Sci 2013;14:358.
Brothers SP, Wahlestedt C: Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med 2010;2:429.
Pedragosa-Badia X, Stichel J, Beck-Sickinger AG: Neuropeptide Y receptors: How to get subtype selectivity. Front Endocrinol 2013;4:5.
Saraf R et al: Neuropeptide Y is an angiogenic factor in cardiovascular regeneration. Eur J Pharmacol 2016;776:64.